Abstract
In the field of inflammation imaging, nuclear medicine techniques can be considered as a non-invasive tool to early detect pathophysiological changes in affected tissues. These changes usually occur before clinical onset of symptoms and before the development of anatomical changes, that are commonly detected by radiological procedures. This is particularly important for prognostic purposes, therapy decision making and for therapy follow-up. Here we review the current state-of-the art of nuclear medicine for diagnostic purposes in different conditions characterized by a chronic inflammation, such as vulnerable atherosclerotic plaques, vasculitis, rheumatoid arthritis, Sjogren syndrome, autoimmune thyroid diseases, inflammatory bowel diseases, Coeliac disease, Type 1 diabetes mellitus and other immunological diseases. Overall, we describe several different approaches based on radiolabeled cells, peptides and antibodies or FDG. It emerges the role of PET and of hybrid cameras in particular (SPECT/CT and PET/CT) for diagnosis of these disorders and for therapy decision making and followup.
Keywords: Molecular imaging, inflammation, nuclear medicine, atherosclerotic plaques, vasculitis, antibodies.
Current Pharmaceutical Design
Title:Current Status of Molecular Imaging in Inflammatory and Autoimmune Disorders
Volume: 24 Issue: 7
Author(s): Alberto Signore*, Kelly Luz Anzola, Sveva Auletta, Michela Varani, Agnese Petitti, Marta Pacilio, Filippo Galli and Chiara Lauri
Affiliation:
- Nuclear Medicine Unit, Department of Medical-Surgical Sciences and of Translational Medicine, Faculty of Medicine and Psychology, ,Italy
Keywords: Molecular imaging, inflammation, nuclear medicine, atherosclerotic plaques, vasculitis, antibodies.
Abstract: In the field of inflammation imaging, nuclear medicine techniques can be considered as a non-invasive tool to early detect pathophysiological changes in affected tissues. These changes usually occur before clinical onset of symptoms and before the development of anatomical changes, that are commonly detected by radiological procedures. This is particularly important for prognostic purposes, therapy decision making and for therapy follow-up. Here we review the current state-of-the art of nuclear medicine for diagnostic purposes in different conditions characterized by a chronic inflammation, such as vulnerable atherosclerotic plaques, vasculitis, rheumatoid arthritis, Sjogren syndrome, autoimmune thyroid diseases, inflammatory bowel diseases, Coeliac disease, Type 1 diabetes mellitus and other immunological diseases. Overall, we describe several different approaches based on radiolabeled cells, peptides and antibodies or FDG. It emerges the role of PET and of hybrid cameras in particular (SPECT/CT and PET/CT) for diagnosis of these disorders and for therapy decision making and followup.
Export Options
About this article
Cite this article as:
Signore Alberto *, Anzola Luz Kelly , Auletta Sveva , Varani Michela , Petitti Agnese , Pacilio Marta, Galli Filippo and Lauri Chiara, Current Status of Molecular Imaging in Inflammatory and Autoimmune Disorders, Current Pharmaceutical Design 2018; 24 (7) . https://dx.doi.org/10.2174/1381612824666180130115153
DOI https://dx.doi.org/10.2174/1381612824666180130115153 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
?Revolutionizing Cancer Treatment: Nano-Therapeutics Targeting Tumor Microenvironment?
This thematic issue explores the forefront of cancer treatment, centering on the groundbreaking potential of nano-therapeutics meticulously designed to target the tumor microenvironment. At its core, the issue aims to unravel the latest advancements in nanotechnology, showcasing innovative materials, formulations, and delivery systems that hold promise for redefining cancer therapeutics. ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer?s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gastroenterological Complications of Anderson-Fabry Disease
Current Pharmaceutical Design Secondary Hypertension: The Ways of Management
Current Vascular Pharmacology Crohns Targeted Therapy: Myth or Real Goal?
Current Drug Discovery Technologies Privileged Structures - Dream or Reality: Preferential Organization of Azanaphthalene Scaffold
Current Medicinal Chemistry The Role of Anti-Inflammatory Drugs in Respiratory Diseases - Pirfenidone, Penicillamine, Chloroquine and Chlorambucil
Current Respiratory Medicine Reviews Role of Oxidized Phospholipids in Acute Lung Injury
Current Respiratory Medicine Reviews Use of Diffusion- and Perfusion-Weighted Magnetic Resonance Imaging in Drug Development for Ischemic Stroke
Current Drug Targets - CNS & Neurological Disorders A Systematic Approach to Hypertensive Urgencies and Emergencies
Current Hypertension Reviews Current Therapeutic Drugs Against Cerebral Vasospasm after Subarachnoid Hemorrhage: A Comprehensive Review of Basic and Clinical Studies
Current Drug Delivery Connexins in Renal Endothelial Function and Dysfunction
Cardiovascular & Hematological Disorders-Drug Targets Clinical Utility of Biomarkers in Premature Atherosclerosis
Current Medicinal Chemistry Rheumatologic Aspects of the COVID-19 Pandemic: A Practical Resource for Physicians in Kuwait and the Gulf region as Recommended by the Kuwait Association of Rheumatology
Current Rheumatology Reviews N-Methyl D-Aspartate (NMDA) Receptor Antagonists and Memantine Treatment for Alzheimer’s Disease, Vascular Dementia and Parkinson’s Disease
Current Alzheimer Research L-PRP/L-PRF in Esthetic Plastic Surgery, Regenerative Medicine of the Skin and Chronic Wounds
Current Pharmaceutical Biotechnology Inhibition of Interleukin-1 in the Treatment of Selected Cardiovascular Complications
Current Reviews in Clinical and Experimental Pharmacology Human Endogenous Retroviruses in Multiple Sclerosis: Potential for Novel Neuro-Pharmacological Research
Current Neuropharmacology Endogenous Cardioprotective Agents: Role in Pre and Postconditioning
Current Drug Targets Cytostatic Properties of Some Angiotensin I Converting Enzyme Inhibitors and of Angiotensin II Type I Receptor Antagonists
Current Pharmaceutical Design Therapeutical Approaches of Vasoactive Intestinal Peptide as a Pleiotropic Immunomodulator
Current Pharmaceutical Design Remodelling of the Ca2+ Toolkit in Tumor Endothelium as a Crucial Responsible for the Resistance to Anticancer Therapies
Current Signal Transduction Therapy